{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:29:41Z","timestamp":1790270981637,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Scalp, nail, and palmoplantar psoriasis are termed \u201cdifficult-to-treat sites\u201d owing to their unique anatomical features and therapeutic resistance, substantially impairing patient quality of life. Although anti-IL-17 and anti-IL-23 biologics are widely used, head-to-head comparative evidence for achieving high-level lesion clearance at these specific sites remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA-NMA guidelines, we systematically searched PubMed, Embase, and other databases from inception through November 2025 for randomized controlled trials (RCTs). Primary outcomes were defined as complete or near-complete clearance. Frequentist network meta-analysis was performed to calculate odds ratios (ORs), with treatment rankings derived from surface under the cumulative ranking curve (SUCRA) values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-four RCTs involving 5,946 patients and eight biologics plus placebo were included. For palmoplantar psoriasis, secukinumab ranked highest (SUCRA\u00a0=\u00a079.7%), followed by bimekizumab (72.2%) and ustekinumab (69.7%). For nail psoriasis, bimekizumab ranked first (78.9%), followed by ixekizumab (77.2%) and brodalumab (67.5%); however, local inconsistency for the ixekizumab\u2013placebo comparison and low-certainty evidence warrant caution. For scalp psoriasis, brodalumab (87.7%) and ixekizumab (86.9%) ranked highest, followed by bimekizumab (69.0%) and guselkumab (65.1%); the brodalumab estimate relied on a single contributing study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>During induction-phase follow-up, IL-17 inhibitors tended to rank highly for complete or near-complete clearance at difficult-to-treat psoriasis sites. Bimekizumab and ixekizumab showed consistently favorable rankings across sites, but treatment selection should consider certainty of evidence, sensitivity analyses, long-term response, and patient-level factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>\n                      , identifier CRD420251271255.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1846290","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:53:39Z","timestamp":1784699619000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Short-term efficacy of biologics targeting the IL-17\/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Shouxu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TszLeong","family":"Lam","sequence":"additional","affiliation":[{"name":"Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Hospital of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haomin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Hospital of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/life15030425","article-title":"Hard-to-treat areas in psoriasis: An underevaluated part of the disease","volume":"15","author":"Lupulescu","year":"2025","journal-title":"Life"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000232309","article-title":"Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm\/soles and nails","volume":"38","author":"Kragballe","year":"2009","journal-title":"Curr Probl Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1067\/s0190-9622(03)01479-8","article-title":"Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice","volume":"49","author":"Pettey","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12368","article-title":"Nail psoriasis, the unknown burden of disease","volume":"28","author":"Klaassen","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","article-title":"Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails","volume":"31","author":"Merola","year":"2018","journal-title":"Dermatol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1749546","article-title":"Efficacy of brodalumab in the treatment of scalp and nail psoriasis: Results from three phase 3 trials","volume":"33","author":"Elewski","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0191-7","article-title":"Palmoplantar psoriasis and palmoplantar pustulosis: Current treatment and future prospects","volume":"17","author":"Raposo","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142633","article-title":"Nail psoriasis: A review of the literature","volume":"89","author":"Schons","year":"2014","journal-title":"Bras Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"Recategorization of psoriasis severity: Delphi consensus from the international psoriasis council","volume":"82","author":"Strober","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621956","article-title":"Major role of the IL17\/23 axis in psoriasis supports the development of new targeted therapies","volume":"12","author":"Bugaut","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub7","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"8","author":"Sbidian","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01295-w","article-title":"Bimekizumab efficacy in high-impact areas: Pooled 2-year analysis in scalp, nail, and palmoplantar psoriasis from phase 3\/3b randomized controlled trials","volume":"14","author":"Merola","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator\u2013controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.10.064","article-title":"Systemic therapy in treating palmoplantar and scalp psoriasis: A systematic review and network meta-analysis","volume":"90","author":"Zhang","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: An introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111716","article-title":"Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis","volume":"130","author":"Xia","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2272049","article-title":"Efficacy of biologic agents for palmoplantar psoriasis: A systematic review and network meta-analysis","volume":"19","author":"Tsiogkas","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14237","article-title":"Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: Results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)","volume":"31","author":"Menter","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"178","author":"Papp","year":"2018","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1249820","article-title":"Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: Results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"28","author":"Reich","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"B25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1521","article-title":"A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement","volume":"91","author":"Lebwohl","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/9967747","article-title":"A phase IIIb, multicentre, interventional, randomised, placebo-controlled clinical trial investigating the efficacy and safety of guselkumab for the treatment of nonpustular palmoplantar psoriasis (G-PLUS)","volume":"2023","author":"Passeron","year":"2023","journal-title":"Dermatol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02976-w","article-title":"Efficacy of ixekizumab in Chinese patients with moderate-to-severe psoriasis and special body area involvement: Sub-analysis of a randomized, double-blind, multicenter phase 3 study","volume":"42","author":"Li","year":"2025","journal-title":"Adv Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00383-x","article-title":"Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S)","volume":"10","author":"Wasel","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005522","article-title":"Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: A pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies","volume":"11","author":"Coates","year":"2025","journal-title":"RMD Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf327","article-title":"SPECTREM phase 3b clinical trial results through week 16: Guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement","volume":"194","author":"Stein Gold","year":"2025","journal-title":"Br J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01544-6","article-title":"Efficacy and safety of risankizumab in genital or scalp psoriasis in the UnlIMMited phase 4 randomized clinical trial at week 16","volume":"16","author":"Song","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14504","article-title":"Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"J Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1849","article-title":"Guselkumab for moderate to severe scalp psoriasis across all skin tones: Cohort B of the VISIBLE randomized clinical trial","volume":"161","author":"McMichael","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.025","article-title":"Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, phase 3b study","volume":"91","author":"Gebauer","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: A meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02976-w","article-title":"Efficacy of ixekizumab in Chinese patients with moderate-to-severe psoriasis and special body area involvement: Subanalysis of a randomized, double-blind, multicenter phase 3 study","volume":"42","author":"Li","year":"2025","journal-title":"Adv Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000504841","article-title":"Characterization of patients with psoriasis in challenging-to-treat body areas in the corrona psoriasis registry","volume":"237","author":"Callis Duffin","year":"2020","journal-title":"Dermatology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-025-00789-2","article-title":"Comparative efficacy and safety of IL-17 and IL-23 inhibitors for moderate-to-severe psoriasis in asian populations: A systematic review and meta-analysis","volume":"27","author":"Alzghool","year":"2026","journal-title":"BMC Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00849-0","article-title":"Small-molecule inhibitors and biologics for palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis","volume":"25","author":"Huang","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.043","article-title":"Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials","volume":"89","author":"Spencer","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1892024","article-title":"Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis","volume":"33","author":"Reich","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B49","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/ced\/llad136","article-title":"Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis","volume":"48","author":"Husein-ElAhmed","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00521-z","article-title":"Scalp psoriasis: A literature review of effective therapies and updated recommendations for practical management","volume":"11","author":"Mosca","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-018-0888-4","article-title":"Brodalumab: A review in moderate to severe plaque psoriasis","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00746-6","article-title":"Narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis","volume":"12","author":"Menter","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051058","article-title":"Comparison of the efficacy and safety of biologics (secukinumab, ustekinumab, and guselkumab) for the treatment of moderate-to-severe psoriasis: Real-world data from a single korean center","volume":"10","author":"Jung","year":"2022","journal-title":"Biomedicines"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-026-01662-9","article-title":"Real-world efficacy of IL-23 inhibitors in psoriasis affecting high-impact areas: Indirect comparison of tildrakizumab 200 mg, risankizumab, and guselkumab\u2014IL PSO (italian landscape psoriasis)","volume":"16","author":"Trovato","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01150-y","article-title":"Baseline characteristics and mNAPSI change from baseline scores through month 12 for patients with moderate-to-severe plaque psoriasis and concomitant nail psoriasis treated with biologics from PSoHO","volume":"14","author":"Riedl","year":"2024","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1846290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:53:40Z","timestamp":1784699620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1846290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2026.1846290"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1846290","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1846290"}}